Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

§ 01 Executive Snapshot

• What: Rafael Holdings reports its financial results for Q3 FY 2026.
• Who: Rafael Holdings, Inc., Chief Operating Officer Joshua Fine, and CEO Howard Jonas.
• Why it matters: The results reflect the company's ongoing transition into a commercial-stage biotechnology firm, with significant implications for its future market positioning and shareholder value.

§ 02 Key Developments

• The completion of the last patient visit in the Phase 3 TransportNPC™ trial, a pivotal study for treating Niemann-Pick Disease Type C1 (NPC1).
• Cash and cash equivalents amount to $30.5 million as of April 30, 2026.
• Net loss of $4.2 million for Q3 FY 2026, down from a net loss of $4.8 million in the same period last year.
• Research and development expenses rose to $4.9 million for Q3 FY 2026, compared to $3.0 million in the previous year due to the acquisition of Cyclo Therapeutics.
• Expected submission of the New Drug Application (NDA) in the second half of calendar 2026 following a pre-NDA meeting with the FDA.

§ 03 Strategic Context

• Rafael Holdings is evolving from a developmental stage to a commercial-stage biotechnology company, which is crucial for unlocking potential value in the unmet medical needs of NPC.
• The acquisition of Cyclo Therapeutics marks a significant strategic step, consolidating expertise and resources that could enhance Rafael's product pipeline and market reach.

§ 04 Strategic Implications

• The completion of the Phase 3 trial positions Rafael Holdings favorably for potential FDA approval, which could lead to market entry and revenue generation.
• The consolidation of Cyclo Therapeutics’ expenses indicates a strategic investment in R&D that could yield long-term returns and strengthen the company’s competitive edge in rare disease markets.

§ 05 Risks & Constraints

• The company faces regulatory risks associated with the FDA approval process, which could delay market entry.
• Competition in the biotechnology sector, especially in the rare disease space, may impact market share and pricing strategies.

§ 06 Watchlist / Forward Signals

• Anticipated NDA submission in the second half of calendar 2026, which will be a critical milestone for the company's future.
• Monitoring the clinical outcomes from the Phase 3 trial and subsequent FDA feedback will be vital for assessing the commercial viability of their lead candidate.